Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants orphan drug designation to Advaxis' ADXS-cHER2 for osteosarcoma

May 28, 2014

FDA grants orphan drug status to SAR-650984 for cancer

May 28, 2014

Cel-Sci expands phase III study of Multikine to new U.S. site

May 28, 2014

BioInvent sells back ADC-1013 rights to Alligator Bioscience

May 28, 2014

European researchers disclose new anti-S100-A4 MAbs

May 27, 2014

Daiichi Sankyo receives additional indication approval in Japan for Ranmark

May 27, 2014

EMA committee recommends approval of obinutuzumab

May 26, 2014

GSK and Genmab report topline data from pivotal head-to-head study of ofatumumab

May 21, 2014

MOR-208 receives FDA and EMA orphan drug designations

May 21, 2014

ADC Therapeutics and MedImmune to advance ADCT-401 into clinic

May 21, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...